Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.50M | -1.55M | -1.45M | -1.38M | -981.00K |
| Total Depreciation and Amortization | 37.80K | 49.50K | 9.70K | 12.00K | 14.60K |
| Total Amortization of Deferred Charges | 45.80K | 34.30K | 69.50K | 58.10K | 46.90K |
| Total Other Non-Cash Items | 510.90K | 594.50K | 914.80K | 1.04M | 699.50K |
| Change in Net Operating Assets | 243.90K | 124.50K | -78.50K | -251.00K | -201.20K |
| Cash from Operations | -657.70K | -748.20K | -536.10K | -518.50K | -421.10K |
| Capital Expenditure | -2.10K | -2.10K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -512.20K | -644.30K | -832.30K | -953.50K | -143.10K |
| Cash from Investing | -514.30K | -646.40K | -832.30K | -953.50K | -143.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.59M | 1.63M | 1.66M | 2.39M | 797.50K |
| Repurchase of Common Stock | -3.00K | -3.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.10K | -31.10K | -84.00K | -84.00K | -52.90K |
| Cash from Financing | 1.09M | 1.12M | 1.10M | 1.64M | 546.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.10K | -275.60K | -266.00K | 164.60K | -17.90K |